Back to top

Analyst Blog

Mylan (MYL - Analyst Report) extended its three-year old partnership with India-based Biocon Limited. The companies recently signed a definitive agreement to develop and commercialize the generic versions of three insulin analog products.

As per the terms of the agreement Mylan will have the rights to develop and commercialize Biocon's Glargine, Lispro and Aspart. Glargine is the generic version of Sanofi's (SNY - Analyst Report) Lantus; Lispro is the generic of Eli Lilly and Company's (LLY - Analyst Report) Humalog while Aspart is the generic of Novo Nordisk's (NVO - Analyst Report) NovoLog.

Mylan gained the exclusive commercialization rights of these products in the US, Canada, Australia, New Zealand, the EU and the European Free Trade Association countries. Mylan and Biocon will share development, capital and other expenses in respect to the commercial launch of the products. The company has a profit-sharing arrangement with Biocon for the commercialization of the products in these areas.

Mylan enjoys co-exclusive commercialization rights with Biocon for these products in some other markets around the world. The companies however kept the other terms of the agreement under cover.

Mylan mentioned in its press release that worldwide collaborated net sales of Lantus, Humalog and NovoLog for 2012 were around $11.5 billion.

We note that Mylan already has a strategic collaboration with Biocon to develop a biogenerics portfolio with five products.

The company has several agreements with big pharmaceutical companies in diverse areas. Mylan is set to report its fourth quarter and full year financial results on Feb 27. We expect investor focus to remain on the company’s financial results.

Mylan currently carries a Zacks Rank #2 (Buy). Meanwhile, Sanofi, Lilly and Novo Nordisk also carry a comparable rank.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
FELCOR LODG… FCH 10.47 +3.46%
OLD DOMINIO… ODFL 63.48 +1.18%
VASCO DATA… VDSI 13.57 +0.67%
AMEDISYS IN… AMED 20.18 +0.10%
LENOVO GROU… LNVGY 27.07 +0.04%